UPDATED May 1, 2019, with milestone terms. Merit Medical (NSDQ:MMSI) said yesterday that it put $60 million on the table to acquire Vascular Insights and its ClariVein line of catheters, including a $20 million milestone pegged to sales targets. Quincy, Mass.-based Vascular Insights makes the ClariVeinIC and ClariVeinOC infusion and occlusion catheters for treating superficial […]
CardioMech taps medtech vet Nehm for CEO | Personnel Moves, November 5, 2018
CardioMech taps medtech veteran Nehm for CEO Swedish mitral valve repair company CardioMech said today that it named medical device industry veteran Richard Nehm as president & CEO effective immediately. Nehm’s resume includes stints at Boston Scientific (NYSE:BSX), Abbott (NYSE:ABT) acquisition Tendyne and ATS Medical (acquired by Medtronic (NYSE:MDT)). CardioMech also named Spinal Stabilization Technologies president […]
Sunrise Labs executes succession plan | Personnel Moves – April 5, 2018
Medical device and life science development group Sunrise Labs said this week that it completed its succession plan, with president Eric Soederberg acquiring the majority of shares in the company through a stock sale with founder and board chair Drew Sunstein. With the transaction, the Bedford, N.H.-based company said that it secured its planned ownership […]
Connecticut device makers tout approvals for surgical implements
A pair of Connecticut medical device firms won regulatory nods in the U.S. and Europe.
SurgiQuest Inc. won 510(k) clearance from the Food & Drug Administration for its new line of 5mm AnchorPort laparoscopy trocars and Vascular Insights LLP landed CE Mark approval in Europe for its ClariVein Occlusion Catheter.
SurgiQuest touts its device’s ability to adjust for differences in each patient, calling it "the world’s first elastomeric single incision laparoscopy kit."
Vascular Insights touts clinical trial of ClariVein catheter
Vascular Insights is touting the results of an independent clinical trial examining the use of its ClariVein catheter to treat varicose veins.
The trial, conducted by Dr. Steve Elias of Mount Sinai Hospital in New York, indicated that the ClariVein procedure was as successful initially as radiofrequency or laser treatment, according to a press release.
